Rallybio shares gain on investment from J&J for rare fetal condition treatment [Seeking Alpha]
Rallybio Corporation (RLYB)
Company Research
Source: Seeking Alpha
development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia. In addition, Rallybio received an equity investment of $6.6 million from Johnson & Johnson, the company said. Rallybio ( RLYB ) is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing, thereby eliminating the risk of FNAIT and its potentially devastating consequences in their fetuses and newborns. Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. "Rallybio is on track to initiate a Phase 2 dose confirmation study for RLYB212 in pregnant individuals at higher risk of alloimmunization and FNAIT in the second half of 2024," the company said. Under this collaboration, Johnson & Johnson will provide funding for Rallybio to raise awareness of Johnson & Johnson's FNAIT
Show less
Read more
Impact Snapshot
Event Time:
RLYB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLYB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLYB alerts
High impacting Rallybio Corporation news events
Weekly update
A roundup of the hottest topics
RLYB
News
- Rallybio Co. (NASDAQ: RLYB) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.MarketBeat
- FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual MeetingBusiness Wire
- RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up [Yahoo! Finance]Yahoo! Finance
- Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at Wedbush from $13.00 to $11.00. They now have an "outperform" rating on the stock.MarketBeat
- J&J, Rallybio partner on drug development for rare fetal condition [Yahoo! Finance]Yahoo! Finance
RLYB
Earnings
- 3/12/24 - Miss
RLYB
Sec Filings
- 4/22/24 - Form D
- 4/11/24 - Form DEF
- 4/10/24 - Form 8-K
- RLYB's page on the SEC website